Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer

Mayo Clinic Proceedings

Volumn 85, Issue 12, 2010, Pages 1111-1120

  Pruthi, Sandhya ^a   Gostout, Bobbie S ^a   Lindor, Noralane M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EXEMESTANE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGITAL MAMMOGRAPHY; DISEASE PREDISPOSITION; DRUG COST; DRUG TOLERABILITY; ECHOMAMMOGRAPHY; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SUBCUTANEOUS MASTECTOMY; SURGICAL RISK; THROMBOEMBOLISM;

EID: 78650078754     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0414     Document Type: Review

References (85)

1. Lindor NM, McMaster ML, Lindor CJ, Greene MH; National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group. Concise handbook of familial cancer susceptibility syndromes: second edition. J Natl Cancer Inst Monogr. 2008;2008(38):1-93.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-710.
4. ACOG. The American Congress of Obstetricians and Gynecologists Web site. Washington, DC: American Congress of Obstetricians and Gynecologists ACOG; http://www.acog.org/from-home/proxy/. Accessed September 20, 2010.
5. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665-676.
6. Jatoi I, Anderson WF. Management of women who have a genetic predisposition for breast cancer. Surg Clin North Am. 2008;88(4):845-861.
7. Andrieu N, Goldgar DE, Easton DF, et al. EMBRACE; GENEPSO; GEO-HEBON; IBCCS Collaborators Group. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535-544.
8. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies [published correction appears in Am J Hum Genet. 2003;73(3):709]. Am J Hum Genet. 2003;72(5):1117-1130.
9. Antoniou AC, Rookus M, Andrieu N, et al. EMBRACE; GENEPSO; GEOHEBON. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009;18(2):601-610.
10. Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7(5):R833-R843.
11. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001;61(14):5420-5424. (Pubitemid 32694921)
12. Andrieu N, Smith T, Duffy S, et al. The effects of interaction between familial and reproductive factors on breast cancer risk: a combined analysis of seven case-control studies. Br J Cancer. 1998;77(9):1525-1536. (Pubitemid 28190757)
13. McLaughlin JR, Risch HA, Lubinski J, et al.; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26-34.
14. Modugno F, Moslehi R, Ness RB, et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003;14(5):439-446. (Pubitemid 36999978)
15. Passaperuma K, Warner E, Hill KA, Gunasekara A, Yaffe MJ. Is mammographic breast density a breast cancer risk factor in women with BRCA mutations? J Clin Oncol. 2010;28(23):3779-3783.
16. Nkondjock A, Ghadirian P. Epidemiology of breast cancer among BRCA mutation carriers: an overview. Cancer Lett. 2004;205(1):1-8. (Pubitemid 38230132)
17. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRC1 and BRCA2. Science. 2003 Oct 24;302(5645):643-646.
18. Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat. 2006;98(3):285-294. (Pubitemid 44195598)
19. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.
20. National Cancer Institute. Surveillance Research Web site. Where can I find statistics related to the Lifetime Risk of Developing or Dying of Cancer? Updated January 22, 2010. http://surveillance.cancer.gov/statistics/types/ lifetime-risk.html. Accessed September 20, 2010.
21. Robson M, Offit K. Clinical practice: management of an inherited predisposition to breast cancer. N Engl J Med. 2007;357(2):154-162. (Pubitemid 47057733)
22. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358-1365.
23. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
24. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J. 2002;8(1):23-27. (Pubitemid 34118480)
25. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28(2):115-120. (Pubitemid 24056083)
26. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors [published correction appears in Stat Med. 2005;24(1):156]. Stat Med. 2004;23(7):1111-1130.
27. Cuzick J. IBIS Breast Cancer Risk Evaluation Tool Web site. Description of breast cancer risk program. Updated January 31, 2008. http://ems-trials.org/ riskevaluator/. Accessed September 20, 2010.
28. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(3):227-238. (Pubitemid 27073760)
29. UT Southwestern Medical Center. Requesting CancerGene. Dallas, TX: The University of Texas Southwestern Medical Center at Dallas; 2010. http://www8.utsouthwestern.edu/utsw/cda/dept47834/files/68221.html. Accessed September 20, 2010.
30. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement [published correction appears in Ann Intern Med. 2005;143(7):547]. Ann Intern Med. 2005;143(5):355-361.
31. Menon U, Gentry-Maharaj A, Ryan A, et al. Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study [published correction appears in BMJ. 2008;337:a2976]. BMJ. 2008;337:a2079.
32. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807-814.
33. National Society of Genetic Counselors. (nsgc) Web site. National Society of Genetic Counselors, Inc; 1995-2009. http://www.nsgc.org/. Accessed September 20, 2010.
34. Genetic Information Nondiscrimination Act of 2008. Pub L 110-233, 122 Stat. 881 (May 21, 2008).
35. Saslow D, Boetes C, Burke W, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [published correction appears in CA Cancer J Clin. 2007;57(3):185]. CA Cancer J Clin. 2007;57(2):75-89.
36. Spiegel TN, Hill KA, Warner E. The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations. J Womens Health (Larchmt). 2009;18(7):1019-1024.
37. Pisano ED, Gatsonis C, Hendrick E, et al.; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening [published correction appears in N Engl J Med. 2006;355(17):1840]. N Engl J Med. 2005;353(17):1773- 1783.
38. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5, part 1):347-360. (Pubitemid 34977137)
39. Ronckers CM, Doody MM, Lonstein JE, Stovall M, Land CE. Multiple diagnostic X-rays for spine deformities and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(3):605-613.
40. Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst. 2009;101(3):205-209.
41. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001;19(15):3524-3531.
42. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317-1325. (Pubitemid 39223222)
43. Kriege M, Brekelmans CT, Boetes C, et al.; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-437.
44. Weinstein SP, Localio AR, Conant EF, Rosen M, Thomas KM, Schnall MD. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009;27(36):6124-6128.
45. Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force [published correction appears in Ann Intern Med. 2005;143(7):547]. Ann Intern Med. 2005;143(5):362-379.
46. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer. 2004;100(10):2079-2083.
47. National Comprehensive Cancer Network. NCCN & Clinical Resources Web site. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Genetic/familial high-risk assessment: breast and ovarian. Hereditary breast and/or ovarian cancer. Version 1.2010. 2010. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed August 21, 2010.
48. Greene MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17(3):594-604.
49. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25(20):2921-2927.
50. Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published correction appears in 2006;296(24):2926. JAMA. 2007;298(9):973]. JAMA. 2006;295(23):2727-2741.
51. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151(10):703-715, W-226-35.
52. Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706.
53. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
54. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94(23):1773-1779.
55. Bevers TB, Anderson BO, Bonaccio E, et al.; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
56. Li Y, Brown PH. Strategies of hormonal prevention. In: Fuqua SAW, ed. Hormone Receptors in Breast Cancer. New York, NY: Springer; 2009:195-229.
57. Li Y, Brown PH. Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev. 2007;16(3):203-215.
58. Pichert G, Bolliger B, Buser K, Pagani O; Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol. 2003;14(1):9-19.
59. Narod SA, Risch H, Moslehi R, et al.; Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339(7):424-428.
60. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350-356.
61. Haile RW, Thomas DC, McGuire V, et al. kConFab Investigators; Ontario Cancer Genetics Network Investigators. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1863-1870.
62. NIH consensus conference; NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA. 1995;273(6):491-497.
63. Berliner JL, Fay AM; Practice Issues Subcommittee of the National Society of Genetic Counselors' Familial Cancer Risk Counseling Special Interest Group. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16(3):241-260.
64. Hollingsworth AB, Singletary SE, Morrow M, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg. 2004;187(3):349-362.
65. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062. (Pubitemid 41095038)
66. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
67. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331-1337.
68. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87.
69. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 2002;20(10):2520-2529.
70. Anderson K, Jacobson JS, Heitjan DF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144(6):397-406.
71. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21(22):4222-4227.
72. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25(10):1283-1289.
73. Dowdy SC, Stefanek M, Hartmann LC. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol. 2004;191(4):1113-1123.
74. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol. 2009;112(3):594-600.
75. Rebbeck TR, Friebel T, Wagner T, et al.; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804-7810.
76. Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer. 2009;45(1):82-89.
77. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074-1083.
78. Eisen A, Lubinski J, Gronwald J, et al.; Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361-1367.
79. Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr. 2005; 2005(34):83-86.
80. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001;357(9267):1467-1470.
81. Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240-244.
82. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284(3):319-324.
83. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23(31):7849-7856.
84. Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26(24):3943-3949.
85. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222-231.